NCT05999968 2026-03-05
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Eli Lilly and Company
Phase 1 Completed
Clinical Trials
660 trialsNCT07450157 2026-03-04
A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617
Novartis
Completed
NCT04736199 2026-02-27
ARANOTE
Bayer
Phase 3 Completed
NCT01171898 2026-02-24
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
Aragon Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01314118 2026-02-24
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Janssen Biotech, Inc.
Phase 2 Completed
NCT06235099 2026-02-18
Solar-Recur
Curium US LLC
Phase 3 Completed
NCT04397276 2026-02-17
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors
Janssen Research & Development, LLC
Phase 1 Completed
NCT05701007 2026-01-29
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Completed
NCT02003924 2026-01-27
PROSPER
Pfizer
Phase 3 Completed
NCT03338790 2026-01-27
CheckMate 9KD
Bristol-Myers Squibb
Phase 2 Completed
NCT03516110 2026-01-23
PRISME
Ipsen
Completed
NCT06840535 2026-01-06
OncoACP-3
Philogen S.p.A.
Phase 1 Completed
NCT06072196 2025-12-31
A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Pfizer
Completed
NCT02854436 2025-12-22
Galahad
Janssen Research & Development, LLC
Phase 2 Completed
NCT02985957 2025-12-22
CheckMate 650
Bristol-Myers Squibb
Phase 2 Completed
NCT04428788 2025-12-22
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Celgene
Phase 1 Completed
NCT06055946 2025-12-22
BARVANA LONG
Aesculap AG
Completed
NCT00117286 2025-12-18
Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer
Ferring Pharmaceuticals
Phase 2/3 Completed
NCT04034095 2025-12-15
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
Janssen Pharmaceutical K.K.
Completed
NCT07086651 2025-12-08
A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)
Pfizer
Completed
NCT01147965 2025-11-25
QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
NantCell, Inc.
Phase 1/2 Completed
NCT03910660 2025-10-20
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
Phase 1/2 Completed
NCT04838613 2025-10-20
GuidePath
Novartis
Phase 3 Completed
NCT03939689 2025-10-14
ARROW
Progenics Pharmaceuticals, Inc.
Phase 2 Completed
NCT04560452 2025-10-08
Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients
AstraZeneca
Completed
NCT04838626 2025-10-07
GuideView
Novartis
Phase 2/3 Completed
NCT04186845 2025-09-22
Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence
Blue Earth Diagnostics
Phase 3 Completed
NCT05323747 2025-09-16
BP-008
BioProtect
Completed
NCT05354427 2025-09-16
CLP-10095
BioProtect
Completed
NCT06604442 2025-09-11
Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy
Blue Earth Diagnostics
Phase 4 Completed
NCT07014488 2025-09-10
A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT05590793 2025-09-09
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
Ipsen
Phase 3 Completed
NCT05946603 2025-09-04
IS-002 Phase 2 Prostate Cancer Study
Intuitive Surgical
Phase 2 Completed
NCT05605964 2025-08-17
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT04553926 2025-08-14
OLAP
AstraZeneca
Completed
NCT05202301 2025-08-11
A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely
Bayer
Completed
NCT05177042 2025-07-25
Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Arvinas Inc.
Phase 1 Completed
NCT03199586 2025-07-20
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Novita Pharmaceuticals, Inc.
Phase 1 Completed
NCT03834506 2025-07-18
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05005728 2025-07-17
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Xencor, Inc.
Phase 2 Completed
NCT04742361 2025-07-15
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
ABX advanced biochemical compounds GmbH
Phase 3 Completed
NCT05171387 2025-06-22
Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer
Bayer
Phase 2 Completed
NCT04100018 2025-06-12
CheckMate 7DX
Bristol-Myers Squibb
Phase 3 Completed
NCT05253053 2025-06-12
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
Phase 1/2 Completed
NCT03072238 2025-06-06
IPATential150
Hoffmann-La Roche
Phase 3 Completed
NCT06151418 2025-06-04
A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces
Pfizer
Completed
NCT05735652 2025-05-30
An Observational Study of Radiotherapy After Injection of SpaceOAR Hydrogel
Boston Scientific Corporation
Completed
NCT04068896 2025-05-29
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
Phase 1/2 Completed
NCT05801965 2025-05-25
A Digital Therapeutic Solution for Cancer Patients
Sidekick Health
Phase NA Completed
NCT06389695 2025-05-21
Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients
Norroy Bioscience Co., LTD
Phase 1/2 Completed